Overview

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

Status:
Recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects with DSM-5 Schizophrenia

Phase:

Phase 3

Details

Lead Sponsor:

Karuna Therapeutics

Collaborator:

Zai Lab (Shanghai) Co., Ltd.

Treatments:

Trospium chloride
Xanomeline